The Technical AnalystExchange: HKSE Sector: Healthcare Industry: Medical Care Facilities
Jinxin Fertility Group Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.41% HKD2.79
America/New_York / 2 mai 2024 @ 23:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7 515.88 mill |
| EPS: | 0.130 |
| P/E: | 21.46 |
| Earnings Date: | Mar 27, 2024 |
| SharesOutstanding: | 2 693.86 mill |
| Avg Daily Volume: | 14.20 mill |
| RATING 2024-05-02 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.62x |
| Company: PE 21.46 | sector: PE 34.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.40x |
| Company: PE 21.46 | industry: PE 53.97 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD1.262 (-54.75%) HKD-1.528 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
HKD 2.71 - 2.95 ( +/- 4.13%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD2.79 (-1.41% ) |
| Volume | 4.62 mill |
| Avg. Vol. | 14.20 mill |
| % of Avg. Vol | 32.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 1951.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
1951.HK
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.